这项研究的目的是调查光疗对生物蝶呤(BH4)的整体影响,新蝶呤(BH2),色氨酸(Trp),卒中后抑郁患者的行为神经炎症反应。从2021年2月至2022年12月,我院共有100名中风后抑郁症住院患者。参与者被随机分配到对照组或实验组。对照组给予常规治疗,包括药物治疗和心理支持,实验组每天接受30分钟的光疗,共8周。所有参与者自愿参与研究并提供知情同意书。对患者的基线特征进行统计学分析。使用汉密尔顿抑郁量表(HAMD)和贝克抑郁量表(BDI)评估抑郁症状的严重程度。氨基酸神经递质的水平,包括γ-氨基丁酸(GABA),天冬氨酸(Asp),和谷氨酸(Glu),使用放射免疫分析法进行测量。血浆神经炎因子水平,如TNF-α,IL-6和IL-1β分别为,使用ELISA测定。通过HPLC检测BH4、BH2和Trp的血浆水平。SOD的水平,GPx,CAT,使用相应的试剂盒和比色法测量血浆中的MDA和MDA。使用SF-36量表评估生活质量。两组患者基线特征差异无统计学意义(P>0.05)。试验组HAMD、BDI评分低于对照组(P<0.05),提示光疗可以降低卒中后抑郁的严重程度.GABA的水平,Glu,与治疗前比较,两组治疗后Asp和Asp均明显升高(P<0.01)。实验组GABA水平高于对照组(P<0.01),而Glu的水平,Asp低于对照组(P<0.01)。血浆TNF-α水平,实验组IL-6、IL-1β水平明显低于对照组(P<0.05)。此外,实验组BH4、Trp水平明显高于对照组(P<0.05),而实验组BH2水平明显低于对照组(P<0.05)。此外,SOD的水平,GPx,实验组CAT明显高于对照组(P<0.05),实验组MDA水平显著低于对照组(P<0.05)。实验组在身体机能方面得分较高,心理健康,社会功能,总体健康状况与对照组比较(P<0.05)。光疗对BH4,BH2和Trp的代谢产生了深远的影响,以及中风后抑郁症患者的行为神经炎症反应和生活质量。通过其优化神经递质分泌和合成的能力,光疗有效调节神经炎症反应,改善生化参数,增强抗氧化能力,缓解抑郁症状.因此,光疗被认为是卒中后抑郁患者的一种有价值的辅助治疗方法.
The aim of this study was to investigate the overall effects of phototherapy on biopterin (BH4), neopterin (BH2), tryptophan (
Trp), and behavioral neuroinflammatory reaction in patients with post-stroke depression. There involved a total of 100 hospitalized patients with post-stroke depression at our hospital from February 2021 to December 2022. The participants enrolled were randomly assigned to either the control group or the experimental group. The control group received routine treatment, including medication and psychological support, while the experimental group received 30 min of phototherapy daily for 8 weeks. All participantsvoluntarily participated in the study and provided informed consent. Baseline characteristics of the patients were statistically analyzed. The severity of depressive symptoms was evaluated using the hamilton depression scale (HAMD) and the beck depression inventory (BDI). Levels of amino acid neurotransmitters, including gamma-aminobutyric acid (GABA), aspartic acid (Asp), and glutamic acid (Glu), were measured using radioimmunoassay. Plasma levels of neuroinflammatory factors, such as TNF-α, IL-6, and IL-1β were, determined using ELISA. Plasma levels of BH4, BH2, and
Trp were detected by HPLC. Levels of SOD, GPx, CAT, and MDA in plasma were measured using corresponding kits and colorimetry. Quality of life was assessed using the SF-36 scale. There were no differences in baseline characteristic between the two groups (P > 0.05). The HAMD and BDI scores in the experimental group were lower than those in the control group (P < 0.05), indicating phototherapy could reduce the severity of post-stroke depression. The levels of GABA, Glu, and Asp in both groups significantly increased after treatment compared to their respective levels before treatment (P < 0.01).The levels of GABA in the experimental group were higher than those in the control group (P < 0.01),while the levels of Glu, and Asp were lower than those in the control group (P < 0.01). The plasma levels of TNF-α, IL-6, and IL-1β in the experimental group were evidently lower than those in the control group (P < 0.05). Moreover, the levels of BH4 and
Trp in experimental group were significantly higher than those in the control group (P < 0.05), while the levelsof BH2 in the experimental group were significantly lower than the control group (P < 0.05). Additionally, the levels of SOD, GPx, and CAT in the experimental group were evidently higher than those in the control group (P < 0.05), whereas the levels of MDA in the experimental group were significantly lower than control group (P < 0.05). The experimental group showed higher scores in physical function, mental health, social function, and overall health compared to the control group (P < 0.05). Phototherapy exerted a profound impact on the metabolism of BH4, BH2, and
Trp, as well as on behavioral neuroinflammatory reactions and the quality of life in patients suffering from post-stroke depression. Through its ability to optimize the secretion and synthesis of neurotransmitters, phototherapy effectively regulated neuroinflammatory reactions, improved biochemical parameters, enhancedantioxidant capacity, and alleviated depressive symptoms. As a result, phototherapy was considered a valuable adjuvant therapeutic approach for patients with post-stroke depression.